Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer
Blocking the mitogen-activated protein kinase (MAPK) pathway with the MEK1/2 inhibitor trametinib has produced promising results in patients with head and neck squamous cell carcinoma (HNSCC). In the current study, we showed that trametinib treatment leads to overexpression and activation of the epi...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
27 July 2023
|
| Ausgabe: | Online version of record before inclusion in an issue |
| In: |
Molecular oncology
Year: 2023, Jahrgang: 17, Heft: 12, Pages: 2618-2636 |
| ISSN: | 1878-0261 |
| DOI: | 10.1002/1878-0261.13500 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/1878-0261.13500 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/1878-0261.13500 
|
| Verfasserangaben: | Ofra Novoplansky, Avital B. Shnerb, Divyasree Marripati, Sankar Jagadeeshan, Raghda Abu Shareb, Cristina Conde-López, Jonathan Zorea, Manu Prasad, Talal Ben Lulu, Ksenia M. Yegodayev, Chen Benafsha, Yushi Li, Dexin Kong, Fengshen Kuo, Luc G.T. Morris, Ina Kurth, Jochen Hess and Moshe Elkabets |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1870256700 | ||
| 003 | DE-627 | ||
| 005 | 20251110133256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231114s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/1878-0261.13500 |2 doi | |
| 035 | |a (DE-627)1870256700 | ||
| 035 | |a (DE-599)KXP1870256700 | ||
| 035 | |a (OCoLC)1425209660 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Novoplansky, Ofra |e VerfasserIn |0 (DE-588)130986361X |0 (DE-627)1870261461 |4 aut | |
| 245 | 1 | 0 | |a Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer |c Ofra Novoplansky, Avital B. Shnerb, Divyasree Marripati, Sankar Jagadeeshan, Raghda Abu Shareb, Cristina Conde-López, Jonathan Zorea, Manu Prasad, Talal Ben Lulu, Ksenia M. Yegodayev, Chen Benafsha, Yushi Li, Dexin Kong, Fengshen Kuo, Luc G.T. Morris, Ina Kurth, Jochen Hess and Moshe Elkabets |
| 250 | |a Online version of record before inclusion in an issue | ||
| 264 | 1 | |c 27 July 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 17 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.11.2023 | ||
| 520 | |a Blocking the mitogen-activated protein kinase (MAPK) pathway with the MEK1/2 inhibitor trametinib has produced promising results in patients with head and neck squamous cell carcinoma (HNSCC). In the current study, we showed that trametinib treatment leads to overexpression and activation of the epidermal growth factor receptor (EGFR) in HNSCC cell lines and patient-derived xenografts. Knockdown of EGFR improved trametinib treatment efficacy both in vitro and in vivo. Mechanistically, we demonstrated that trametinib-induced EGFR overexpression hyperactivates the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. In vitro, blocking the PI3K pathway with GDC-0941 (pictilisib), or BYL719 (alpelisib), prevented AKT pathway hyperactivation and enhanced the efficacy of trametinib in a synergistic manner. In vivo, a combination of trametinib and BYL719 showed superior antitumor efficacy vs. the single agents, leading to tumor growth arrest. We confirmed our findings in a syngeneic murine head and neck cancer cell line in vitro and in vivo. Taken together, our findings show that trametinib treatment induces hyperactivation of EGFR/PI3K/AKT; thus, blocking of the EGFR/PI3K pathway is required to improve trametinib efficacy in HNSCC. | ||
| 650 | 4 | |a drug resistance | |
| 650 | 4 | |a head and neck cancer | |
| 650 | 4 | |a PI3K and EGFR signaling | |
| 650 | 4 | |a Trametinib | |
| 700 | 1 | |a Shnerb, Avital B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marripati, Divyasree |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jagadeeshan, Sankar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Abu Shareb, Raghda |e VerfasserIn |4 aut | |
| 700 | 1 | |a Conde-Lopez, Cristina |d 1995- |e VerfasserIn |0 (DE-588)1258911884 |0 (DE-627)1805556908 |4 aut | |
| 700 | 1 | |a Zorea, Jonathan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Prasad, Manu |e VerfasserIn |0 (DE-588)1258914611 |0 (DE-627)1805562452 |4 aut | |
| 700 | 1 | |a Ben Lulu, Talal |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yegodayev, Ksenia M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Benafsha, Chen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Li, Yushi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kong, Dexin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kuo, Fengshen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Morris, Luc G. T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kurth, Ina |d 1979- |e VerfasserIn |0 (DE-588)1018535802 |0 (DE-627)690629044 |0 (DE-576)354284207 |4 aut | |
| 700 | 1 | |a Heß, Jochen |d 1971- |e VerfasserIn |0 (DE-588)121902390 |0 (DE-627)705696057 |0 (DE-576)292983417 |4 aut | |
| 700 | 1 | |a Elkabets, Moshe |e VerfasserIn |0 (DE-588)1159592772 |0 (DE-627)1022269550 |0 (DE-576)505057751 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular oncology |d Hoboken, NJ : John Wiley & Sons, Inc., 2007 |g 17(2023), 12, Seite 2618-2636 |h Online-Ressource |w (DE-627)531199800 |w (DE-600)2322586-5 |w (DE-576)271586621 |x 1878-0261 |7 nnas |a Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:12 |g pages:2618-2636 |g extent:17 |a Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1002/1878-0261.13500 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/1878-0261.13500 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20231114 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 121902390 |a Heß, Jochen |m 121902390:Heß, Jochen |d 910000 |d 911000 |d 50000 |e 910000PH121902390 |e 911000PH121902390 |e 50000PH121902390 |k 0/910000/ |k 1/910000/911000/ |k 0/50000/ |p 17 | ||
| 998 | |g 1018535802 |a Kurth, Ina |m 1018535802:Kurth, Ina |d 140000 |e 140000PK1018535802 |k 0/140000/ |p 16 | ||
| 998 | |g 1258911884 |a Conde-Lopez, Cristina |m 1258911884:Conde-Lopez, Cristina |d 140000 |e 140000PC1258911884 |k 0/140000/ |p 6 | ||
| 999 | |a KXP-PPN1870256700 |e 4406615091 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 14.11.2023"],"origin":[{"edition":"Online version of record before inclusion in an issue","dateIssuedDisp":"27 July 2023","dateIssuedKey":"2023"}],"recId":"1870256700","relHost":[{"recId":"531199800","pubHistory":["1.2007 -"],"note":["Gesehen am 25.06.20"],"origin":[{"publisherPlace":"Hoboken, NJ ; Amsterdam [u.a.]","publisher":"John Wiley & Sons, Inc. ; Elsevier","dateIssuedDisp":"2007-","dateIssuedKey":"2007"}],"id":{"issn":["1878-0261"],"eki":["531199800"],"zdb":["2322586-5"]},"language":["eng"],"name":{"displayForm":["Federation of European Biochemical Societies"]},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancerMolecular oncology","part":{"volume":"17","extent":"17","issue":"12","year":"2023","pages":"2618-2636","text":"17(2023), 12, Seite 2618-2636"},"title":[{"title":"Molecular oncology","title_sort":"Molecular oncology"}],"type":{"media":"Online-Ressource","bibl":"periodical"}}],"language":["eng"],"name":{"displayForm":["Ofra Novoplansky, Avital B. Shnerb, Divyasree Marripati, Sankar Jagadeeshan, Raghda Abu Shareb, Cristina Conde-López, Jonathan Zorea, Manu Prasad, Talal Ben Lulu, Ksenia M. Yegodayev, Chen Benafsha, Yushi Li, Dexin Kong, Fengshen Kuo, Luc G.T. Morris, Ina Kurth, Jochen Hess and Moshe Elkabets"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer","title":"Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer"}],"person":[{"display":"Novoplansky, Ofra","given":"Ofra","role":"aut","family":"Novoplansky"},{"family":"Shnerb","given":"Avital B.","display":"Shnerb, Avital B.","role":"aut"},{"family":"Marripati","role":"aut","display":"Marripati, Divyasree","given":"Divyasree"},{"family":"Jagadeeshan","display":"Jagadeeshan, Sankar","given":"Sankar","role":"aut"},{"given":"Raghda","display":"Abu Shareb, Raghda","role":"aut","family":"Abu Shareb"},{"family":"Conde-Lopez","role":"aut","given":"Cristina","display":"Conde-Lopez, Cristina"},{"role":"aut","given":"Jonathan","display":"Zorea, Jonathan","family":"Zorea"},{"role":"aut","display":"Prasad, Manu","given":"Manu","family":"Prasad"},{"family":"Ben Lulu","role":"aut","display":"Ben Lulu, Talal","given":"Talal"},{"family":"Yegodayev","role":"aut","given":"Ksenia M.","display":"Yegodayev, Ksenia M."},{"role":"aut","display":"Benafsha, Chen","given":"Chen","family":"Benafsha"},{"family":"Li","role":"aut","given":"Yushi","display":"Li, Yushi"},{"role":"aut","display":"Kong, Dexin","given":"Dexin","family":"Kong"},{"role":"aut","given":"Fengshen","display":"Kuo, Fengshen","family":"Kuo"},{"given":"Luc G. T.","display":"Morris, Luc G. T.","role":"aut","family":"Morris"},{"family":"Kurth","role":"aut","given":"Ina","display":"Kurth, Ina"},{"display":"Heß, Jochen","given":"Jochen","role":"aut","family":"Heß"},{"family":"Elkabets","role":"aut","display":"Elkabets, Moshe","given":"Moshe"}],"physDesc":[{"noteIll":"Illustrationen","extent":"17 S."}],"id":{"eki":["1870256700"],"doi":["10.1002/1878-0261.13500"]}} | ||
| SRT | |a NOVOPLANSKACTIVATION2720 | ||